Kaftrio (Tezacaftor, Elexacaftor, Ivacaftor)

The combination contains two CFTR correctors—elexacaftor and tezacaftor—that enhance the folding and trafficking of the misfolded CFTR protein to the cell surface. Ivacaftor, a CFTR potentiator, then increases the opening probability of the channel, together restoring chloride transport and improving mucociliary clearance.

The prescribed dose of Kaftrio is individualized by the treating physician based on the patient’s age, weight, and clinical status. Typically, the regimen involves taking one tablet twice daily with a fat‑containing meal, but the exact schedule must be set by a qualified healthcare professional.

Safety data for Kaftrio in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their physician.

To place an order, submit an enquiry on the Kaftrio product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Kaftrio (elexacaftor/tezacaftor/ivacaftor) offers broader coverage of CFTR mutations than earlier combinations such as Orkambi (lumacaftor/ivacaftor) and provides greater improvements in lung function for patients with at least one F508del allele. Its triple‑combination design targets both protein processing and channel gating, resulting in higher efficacy for eligible patients.

Kaftrio tablets should be stored at room temperature, below 25 °C, in the original blister pack. Protect them from excess moisture and direct sunlight. Do not refrigerate or freeze the tablets, and keep them out of reach of children.

Kaftrio is taken orally as a whole tablet. Patients should swallow the tablet with water and a meal that contains fat to maximize absorption. The usual schedule is twice daily, but the exact timing and any dose adjustments are determined by the prescribing clinician.

The most serious adverse events include significant liver injury (elevated transaminases or hepatitis), development of cataracts, severe respiratory reactions such as bronchospasm, and rare cases of pancreatitis. Patients should undergo regular liver function tests and eye examinations, and report any new or worsening symptoms promptly.

Kaftrio is contraindicated in patients with known hypersensitivity to any of its components, in those with severe hepatic impairment, and in individuals younger than 12 years. It should also be avoided in patients who cannot safely take a high‑fat meal or who have conditions that preclude the use of CFTR modulators.